The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
about
Gene expression analysis in RA: towards personalized medicinePreclinical rheumatoid arthritis (autoantibodies): an updated reviewPathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLEIdentification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation.Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationInterferon signature in the blood in inflammatory common variable immune deficiencyStrategies to predict rheumatoid arthritis development in at-risk populations.Endotoxin tolerance in monocytes can be mitigated by α2-interferonA prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgiaScreening of gene signatures for rheumatoid arthritis and osteoarthritis based on bioinformatics analysis.The type I interferon signature in leukocyte subsets from peripheral blood of patients with early arthritis: a major contribution by granulocytesChanges in peripheral blood lymphocyte subsets during arthritis development in arthralgia patients.T cell subsets: an immunological biomarker to predict progression to clinical arthritis in ACPA-positive individualsType I interferon response gene expression in established rheumatoid arthritis is not associated with clinical parameters.Blood chemokine profile in untreated early rheumatoid arthritis: CXCL10 as a disease activity marker.Cytokines as biomarkers in rheumatoid arthritis.Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine.Perception of self: distinguishing autoimmunity from autoinflammation.Value of Biomarkers in the Prevention of Rheumatoid Arthritis.Preclinical Rheumatoid Arthritis: Progress Toward Prevention.Emerging aspects of molecular biomarkers for diagnosis, prognosis and treatment response in rheumatoid arthritis.Type I Interferon Gene Response Is Increased in Early and Established Rheumatoid Arthritis and Correlates with Autoantibody Production.Lateral flow immunoassay with upconverting nanoparticle-based detection for indirect measurement of interferon response by the level of MxA.Circulating Interferon-Inducible Protein IFI16 Correlates With Clinical and Serological Features in Rheumatoid Arthritis.Analysis of serum immune markers in seropositive and seronegative rheumatoid arthritis and in high-risk seropositive arthralgia patients.Which patients presenting with arthralgia eventually develop rheumatoid arthritis? The current state of the art.Profiling microRNAs in individuals at risk of progression to rheumatoid arthritis.The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy.Distinctive expression of T cell guiding molecules in human autoimmune lymph node stromal cells upon TLR3 triggering.Heterogeneity of the Type I Interferon Signature in Rheumatoid Arthritis: A Potential Limitation for Its Use As a Clinical Biomarker.Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy.TANK-Binding Kinase 1-Dependent Responses in Health and Autoimmunity.Overall Downregulation of mRNAs and Enrichment of H3K4me3 Change Near Genome-Wide Association Study Signals in Systemic Lupus Erythematosus: Cell-Specific Effects.Phenotypic and Transcriptomic Analysis of Peripheral Blood Plasmacytoid and Conventional Dendritic Cells in Early Drug Naïve Rheumatoid Arthritis.Losartan, but not Enalapril and Valsartan, Inhibits the Expression of IFN-γ, IL-6, IL-17F and IL-22 in PBMCs from Rheumatoid Arthritis PatientsATG16L1 orchestrates interleukin-22 signaling in the intestinal epithelium via cGAS-STINGAbnormal neutrophil signature in the blood and pancreas of presymptomatic and symptomatic type 1 diabetes
P2860
Q26825706-BC686C67-A08E-4BF6-BED5-56D548344BB5Q26863441-CB30595F-CA1C-4EE1-AAD4-913CBA17139BQ27003201-7F8CA2B5-83BA-4073-A66B-ED450157DEFCQ33766708-642B8BD8-3A3C-4A6D-A889-FB27B7B27720Q33848077-E4257DD6-DADF-4816-91E1-6C836BFC48CCQ34999382-1424D953-CF33-4460-BBC9-D9D6E592D3B9Q36366153-1586B5AE-8AA7-43E5-B867-DCADC2E27AC6Q36607876-266018B9-B011-441F-8316-1B2830487598Q36758594-D585706F-741F-4157-9D22-B25D85A88792Q37083070-3F2AE295-7CDF-45BF-86DE-85BDAA2DFFC2Q37093897-96C68A2C-23BC-426E-BF6D-60B829B570BCQ37258240-B9704519-B80F-4901-990E-1062957848D0Q37282514-6ED30FDE-6D21-46F1-A7A3-F7BEAEAA0F6AQ37498499-F4F41EC1-13FB-4B60-AD47-C8E5D095986BQ37621002-49B573EF-3B64-4C3F-B844-42A653005CD6Q37661549-151DB5BA-B125-4D55-8DBE-0347F0942424Q38335622-C554579A-234B-4548-A60D-7240A8C91EBDQ38474054-313AAE34-374D-4E30-8E03-DE6B5389CF9FQ38655399-CB61ADCD-ED9E-4A51-AA1A-84E3A8E11BC2Q38712937-6C4E0325-26C6-4D3C-84C8-2916F2946C29Q38797638-B3A42C37-3D63-4035-B771-83A869AE6ADDQ38857308-16D6167D-77B7-4D24-9D9C-5B3D986294A8Q40537863-CFC6CE71-0EF3-4BA5-9407-E13271A44910Q40597789-8FDF9576-A47F-49F7-8BBE-0881DBA361D1Q42780638-7A0535DC-7CCF-4133-96AC-DE1F47E61C0DQ46720103-EEB58E03-5DC5-4D01-B6C5-28A320F2813CQ47120186-C7198F28-2FE1-44AF-AF44-207D1F74FA12Q47427257-C6287A92-8175-486F-AC87-5D61C6B6BB25Q47548140-4569C461-B889-4E1C-AA9C-F458D9ED5AEBQ49539654-C4F29CDB-2F60-45F0-BEF3-9B1538C05B61Q51168774-B265BAB1-32E9-41A7-9268-645B61149F1DQ52645929-5B904473-25EF-4886-AFB3-1ADA745E8E61Q52723421-C2DFFBAD-EACF-4466-873F-52D80A6E991DQ55344794-6E3F0358-7E41-4D27-8916-DFC523539ADAQ57074018-A2EEF0CC-DA92-457C-9071-296445687412Q58700139-FFC3360F-3FEA-44DB-B7D3-7E62144F2D70Q59134968-47C0C801-DC9D-4FA4-AF07-FEF7411015AD
P2860
The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
description
article
@en
im Februar 2013 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в лютому 2013
@uk
name
The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
@en
The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
@nl
type
label
The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
@en
The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
@nl
prefLabel
The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
@en
The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
@nl
P2093
P1476
The type I IFN signature as a biomarker of preclinical rheumatoid arthritis
@en
P2093
Cornelis L Verweij
Dirkjan van Schaardenburg
John G Wesseling
Joyce Lübbers
Lotte A van de Stadt
Saskia Vosslamber
P304
P356
10.1136/ANNRHEUMDIS-2012-202753
P407
P577
2013-02-23T00:00:00Z